Wordt geladen...
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
In December 2017, ESMO Open—Cancer Horizons convened a round-table discussion on the background and latest data regarding cyclin-dependent kinase (CDK)4/6 inhibitors with endocrine therapy (ET) in the treatment of endocrine-sensitive breast cancer (BC). A review on this discussion was published in s...
Bewaard in:
| Gepubliceerd in: | ESMO Open |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMJ Publishing Group
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6863664/ https://ncbi.nlm.nih.gov/pubmed/31798979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000565 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|